SCHEDULE: Casdin Capital Boosts BioLife Solutions Stake to 12.4%

Casdin Capital and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 12.4% through a recent share acquisition.

Summary

• Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin (collectively, "Reporting Persons") beneficially own 5,957,165 shares of BioLife Solutions, Inc. Common Stock.
• This represents 12.4% of the Issuer's outstanding shares, based on 47,905,265 shares outstanding as of July 31, 2025.
• The Reporting Persons acquired 750,000 shares of Common Stock on October 15, 2025, at a price of $28.5471 per share.
• The acquisition was funded through the working capital of Casdin Partners Master Fund, L.P.
• The purpose of the transaction is for investment, with no immediate plans for extraordinary corporate changes, but the Reporting Persons reserve the right to propose or effect such changes to maximize shareholder value.

Sentiment

Score: 8

Explanation: The filing indicates a strong vote of confidence from a significant institutional investor, Casdin Capital, through an increased equity stake and a stated intention to maximize shareholder value. This suggests a positive outlook on the company's prospects and potential for future strategic enhancements.

Positives

• A significant institutional investor, Casdin Capital, has increased its stake, indicating confidence in BioLife Solutions, Inc.
• The acquisition of 750,000 shares at $28.5471 per share demonstrates a substantial investment.
• The Reporting Persons explicitly state their intention to maximize shareholder value and may engage with management and the board to explore alternatives.

Risks

• The Reporting Persons reserve the right to dispose of shares or enter into other transactions, which could impact share price.
• The Reporting Persons may act in concert with other shareholders or recommend courses of action to management, potentially leading to strategic shifts or activist pressure.

Future Outlook

The Reporting Persons have acquired shares for investment purposes and reserve the right to engage with management and the board to explore alternatives to maximize shareholder value. They may also act in concert with other shareholders or recommend courses of action.

Industry Context

This filing indicates continued investor interest in the life sciences and biotechnology sector, specifically in companies like BioLife Solutions, Inc., which likely operates within this space. Large institutional stakes and potential for shareholder engagement are common in growth-oriented sectors.

Comparison to Industry Standards

• The 12.4% stake held by Casdin Capital is a significant position, often indicative of a long-term investment thesis or potential for activist engagement, which is a common strategy among specialized funds in the biotech sector.
• Casdin Capital's focus on life sciences investments aligns with other specialized funds like Perceptive Advisors or RA Capital Management, which frequently take substantial stakes in emerging and established biotech firms.
• The acquisition price of $28.5471 per share on October 15, 2025, would need to be compared against BioLife Solutions' historical trading range and peer valuations to assess its relative attractiveness, though this filing does not provide such comparative data.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value if Casdin Capital's engagement leads to strategic improvements. Increased institutional ownership can also lend credibility.
• Management/Board: May face increased scrutiny or pressure from Casdin Capital to consider alternatives for value maximization.

Next Steps

• Reporting Persons may engage in discussions with BioLife Solutions' management and Board of Directors regarding strategies to maximize shareholder value.
• Reporting Persons reserve the right to act in concert with other shareholders for common purposes.
• Reporting Persons may recommend courses of action to management and shareholders.
• Reporting Persons reserve the right to dispose of or enter into other transactions in the shares they beneficially own.

Key Dates

Recommendation

The increased stake by a prominent life sciences investor like Casdin Capital, coupled with their stated intent to maximize shareholder value, signals strong conviction in BioLife Solutions' future prospects. This institutional endorsement and potential for activist engagement could serve as a catalyst for improved performance or strategic initiatives, making the stock an attractive "buy" for investors seeking growth and potential value realization.

Keywords

BioLife Solutions, Casdin Capital, Schedule 13D, Institutional Investment, Shareholder Activism, Common Stock, Equity Stake, Investment Management, Biotechnology, Life Sciences